List of Excipients in Branded Drug CAVERJECT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CAVERJECT	alprostadil	0009-3701	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	CAVERJECT	alprostadil	0009-3701	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	CAVERJECT	alprostadil	0009-3701	LACTOSE

CAVERJECT Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

CAVERJECT is an intracavernosal alprostadil product whose commercial differentiation depends more on excipient compatibility, reconstitution convenience, device performance, and supply reliability than on active-ingredient exclusivity. The core formulation uses a small excipient system centered on lactose, sodium citrate, and alpha-cyclodextrin, with presentation-specific diluent requirements. The strongest commercial opportunities are ready-to-use delivery, preservative reduction, improved refrigerated stability, lower injection pain, and contract-manufacturing platforms for alprostadil products.

What excipients are used in CAVERJECT?

CAVERJECT sterile powder contains alprostadil with lactose, sodium citrate, and alpha-cyclodextrin. The product is supplied as a powder that is reconstituted before intracavernosal injection. CAVERJECT IMPULSE uses a dual-chamber syringe presentation that separates the drug powder from the diluent until administration (Pfizer Labs, 2023).

Component	Function in the product	Commercial relevance
Alprostadil	Active vasodilator	Sensitive to formulation, storage, and delivery conditions
Lactose	Bulking agent and lyophilization support	Low-cost, established parenteral excipient; requires attention to moisture and container closure
Sodium citrate	Buffer and pH-control agent	Supports pH control during storage and reconstitution
Alpha-cyclodextrin	Solubilization and stabilization aid	Can improve handling of poorly water-soluble or unstable drug substances
Sterile diluent	Reconstitutes the powder before injection	Affects usability, preservative exposure, injection comfort, and device configuration
Benzyl alcohol, where present in the labeled diluent	Preservative	Creates a potential product-differentiation opportunity for preservative-free delivery

The precise excipient composition depends on the product presentation and applicable labeling. CAVERJECT and CAVERJECT IMPULSE should not be treated as interchangeable formulation platforms without reviewing the relevant approved labeling and chemistry, manufacturing, and controls documentation.

How does CAVERJECT’s formulation work?

CAVERJECT uses a dry-powder presentation to improve storage stability relative to a fully aqueous alprostadil injection. The drug is reconstituted immediately before administration, reducing the period during which alprostadil remains in solution.

The formulation strategy has four technical objectives:

1. Maintain alprostadil potency through the labeled shelf life.
2. Permit rapid and complete reconstitution.
3. Control pH and osmolality after dilution.
4. Avoid precipitation, adsorption, aggregation, or device-related dose loss.

Alpha-cyclodextrin is particularly relevant because it can improve the apparent solubility and handling of alprostadil. The excipient also creates a formulation-development constraint: concentration, complexation behavior, and reconstitution conditions must remain consistent across vial, syringe, needle, and delivery system configurations.

What formulation risks affect alprostadil?

Alprostadil products face several development risks:

• Chemical degradation during aqueous storage.
• Loss of potency from adsorption to syringe or needle materials.
• Incomplete dissolution after reconstitution.
• Particulate formation.
• pH drift.
• Variability in delivered dose after transfer or injection.
• Pain or local irritation associated with the diluent and formulation.
• Sensitivity to oxygen, light, moisture, and temperature excursions.

A CAVERJECT competitor therefore needs more than the same active ingredient and nominal strength. It must demonstrate dose uniformity, sterility, stability, container-closure integrity, and reliable administration through the intended device.

What formulation patents protect CAVERJECT?

CAVERJECT’s original active-ingredient protection is no longer the primary commercial barrier. Alprostadil is an established active ingredient, and the product was approved decades ago. The relevant patent risk is more likely to involve specific formulations, device configurations, manufacturing processes, or delivery systems than the alprostadil molecule itself.

Protection category	Likely commercial status	Competitive impact
Alprostadil composition of matter	Expired or commercially exhausted	Low barrier to generic development
Original CAVERJECT formulation	Largely historic	Limited barrier unless a later patent remains enforceable
Lyophilization process	Potentially relevant only if claims remain active and are technically narrow	Moderate process risk
Dual-chamber syringe	Potential device and combination-product claims	Moderate design-around risk
Reconstitution system	May be protected through device, packaging, or method claims	Moderate usability barrier
Injection method of use	Possible historic patent category	Usually limited for generic launch if claims are expired or not listed
Manufacturing know-how	May remain protected as trade secret	Practical barrier rather than exclusionary patent right

The commercial question is not whether CAVERJECT once had patents. It is whether any unexpired, enforceable claims cover the specific generic or reformulated product under development. That analysis requires a live review of U.S. Patent and Trademark Office records, FDA Orange Book listings, patent litigation dockets, and the proposed product’s exact formulation and device.

What is the Orange Book status of CAVERJECT?

CAVERJECT is an FDA-approved alprostadil intracavernosal injection product. The relevant FDA records distinguish the original CAVERJECT vial presentation from CAVERJECT IMPULSE and from generic alprostadil injection products. Orange Book listings may identify patents, exclusivity, dosage forms, and reference-listed-drug relationships, but the presence of a listed patent does not by itself establish that every formulation or device competitor infringes it (U.S. Food and Drug Administration, 2024a).

The original FDA approval dates are commercially important:

Product	Active ingredient	Route	FDA approval history
CAVERJECT	Alprostadil	Intracavernosal	Approved in the 1990s
CAVERJECT IMPULSE	Alprostadil	Intracavernosal	Later presentation with dual-chamber delivery
Generic alprostadil injection products	Alprostadil	Intracavernosal	Approved through abbreviated pathways where applicable

CAVERJECT does not benefit from new chemical entity exclusivity today. Pediatric exclusivity and other regulatory exclusivities also do not represent the main market barrier for this legacy product.

When does CAVERJECT lose exclusivity?

CAVERJECT’s practical exclusivity period has already ended. The product’s commercial protection is now based primarily on brand recognition, physician familiarity, product availability, device convenience, and manufacturing scale.

For a generic or alternative product, the main regulatory pathways are:

• ANDA approval for a pharmaceutically equivalent and bioequivalent product, where FDA requirements can be met.
• 505(b)(2) approval for a materially different formulation, delivery system, or clinical-use profile.
• A combination-product pathway where a new drug-device configuration changes the regulatory analysis.

The distinction matters. A conventional generic may compete on price but inherit the complexity of reconstitution and injection. A 505(b)(2) product may support a stronger commercial proposition, such as a ready-to-use formulation or a redesigned delivery device, but usually faces greater development and clinical-evidence requirements (U.S. Food and Drug Administration, 2023).

What generic entry risks exist for CAVERJECT?

Generic entry risk is high for the core alprostadil injectable market because:

• The active ingredient is established.
• The product is not protected by new chemical entity exclusivity.
• The dosage form is a conventional injectable presentation.
• The main formulation excipients are familiar pharmaceutical materials.
• The reference product has a long regulatory history.

The principal obstacles are technical rather than fundamental patent barriers. A generic manufacturer must establish:

• Sterility assurance.
• Stability of the dry powder and reconstituted solution.
• Extractables and leachables control.
• Dose uniformity.
• Compatibility with the syringe and needle.
• Reconstitution time and completeness.
• Container-closure integrity.
• Appropriate labeling and user instructions.

Which companies are challenging CAVERJECT?

The relevant competitive group includes manufacturers of generic alprostadil injection, specialty pharmaceutical companies, and contract development and manufacturing organizations with sterile injectable capabilities. The competitive landscape changes by jurisdiction and product availability. Generic suppliers may enter, exit, or experience shortages without changing the underlying patent analysis.

The strongest competitors are not necessarily those with the lowest manufacturing cost. A supplier with reliable sterile fill-finish capacity, validated lyophilization, and an integrated delivery device can obtain a more durable position than a low-cost supplier dependent on a fragile third-party manufacturing network.

What excipient strategies could improve CAVERJECT?

Preservative-free diluent

A preservative-free diluent could reduce concerns about benzyl alcohol exposure and local tolerability, depending on the existing presentation and labeling. The commercial value would be greatest in a single-use, ready-to-administer system where microbial control comes from aseptic manufacture rather than multidose preservation.

The product would need to address:

• Single-use container design.
• Sterility through shelf life.
• Dose preparation time.
• Device compatibility.
• Labeling of storage and use after reconstitution.

Improved buffering system

A revised citrate concentration or alternative buffer could target injection comfort, pH control, and stability. Any buffer change must be assessed against alprostadil degradation, osmolality, local tolerability, and delivered dose.

The opportunity is commercially attractive but technically narrow. A buffer that improves comfort but reduces stability will not create a viable product.

Cyclodextrin optimization

Alpha-cyclodextrin is already part of the CAVERJECT formulation. A competitor could investigate:

• Different cyclodextrin concentration.
• Alternative cyclodextrin grades.
• Complexation conditions.
• Reduced excipient load.
• Faster dissolution after reconstitution.

A different cyclodextrin may support a 505(b)(2) strategy, but it would also create new safety, impurity, and regulatory requirements. The objective should be measurable product improvement rather than excipient substitution alone.

Ready-to-use aqueous formulation

A ready-to-use aqueous formulation would remove the reconstitution step and improve adherence to administration instructions. It is also the most technically demanding option because alprostadil must remain stable in solution during the proposed shelf life.

A viable design may require:

• Oxygen-control packaging.
• Light-protective primary packaging.
• Low-adsorption syringe materials.
• Optimized pH and buffer concentration.
• Refrigerated distribution.
• A validated in-use period.
• A preservative-free single-dose configuration.

This strategy could create meaningful differentiation, but the development program may approach a new product rather than a simple generic.

Polymer and silicone-control strategy

Prefilled syringes and injection devices can introduce adsorption and extractables risks. A lower-silicone or silicone-free system may improve dose consistency and reduce particulate concerns. Device materials should be screened through:

• Agitation studies.
• Temperature cycling.
• Long-term stability.
• Container-closure integrity.
• Extractables and leachables testing.
• Delivered-volume and residual-volume studies.

Pain-reduction strategy

Local tolerability is a commercially relevant product attribute for intracavernosal therapy. Excipient changes could target injection pain through controlled pH, reduced osmolality, elimination of preservatives, or reduced injection volume.

A pain-reduction claim would require clinical support. It should not be inferred from in vitro pH or osmolality data alone.

What manufacturing and intellectual-property barriers affect CAVERJECT alternatives?

The main manufacturing barriers are sterile lyophilization, low-dose content uniformity, alprostadil stability, and device assembly. Alprostadil is administered at microgram strengths, which increases the importance of blend uniformity, fill accuracy, assay sensitivity, and dose-delivery validation.

A commercial manufacturer needs control over:

• Drug-substance quality.
• Low-dose powder blending.
• Lyophilization cycle design.
• Aseptic filling.
• Diluent preparation.
• Dual-chamber or prefilled-device assembly.
• Cold-chain distribution where required.
• Stability-indicating analytical methods.

Trade secrets may be more important than patents in this setting. Lyophilization cycles, oxygen-management procedures, powder handling, and device filling parameters can be difficult to reproduce even when the public formulation is known.

How does CAVERJECT compare with competing erectile-dysfunction products?

Product class	Active ingredient	Administration	Excipient opportunity	Competitive position
CAVERJECT	Alprostadil	Intracavernosal injection	Reconstitution, preservative control, device redesign	Established injectable brand
Compounded intracavernosal mixtures	Often alprostadil with other agents	Intracavernosal injection	Custom concentration and formulation	Variable quality and regulatory status
Sildenafil-class products	PDE5 inhibitors	Oral	Solid-dosage formulation and absorption	First-line oral competition
Tadalafil-class products	PDE5 inhibitors	Oral	Long-duration and combination strategies	Strong oral alternative
Vacuum erection devices	Mechanical	External device	Materials and usability	Nonpharmaceutical competitor
Intracavernosal non-alprostadil products	Other vasoactive agents	Injection	Combination formulation	Potentially stronger efficacy, with different safety risks

CAVERJECT’s commercial market is constrained by the availability of oral PDE5 inhibitors. A successful reformulation must therefore offer a clear benefit in convenience, onset, tolerability, reliability, or use in patients who do not respond adequately to oral therapy.

What licensing opportunities exist around CAVERJECT excipients?

The most practical licensing opportunities are likely to involve enabling technologies rather than CAVERJECT’s core active ingredient. Relevant assets include:

• Ready-to-use alprostadil formulations.
• Low-adsorption prefilled syringes.
• Dual-chamber injection systems.
• Oxygen-scavenging or oxygen-controlled packaging.
• Lyophilization platforms.
• Preservative-free sterile diluent systems.
• Cyclodextrin-based stabilization technology.
• Contract sterile fill-finish capacity.

A licensee should prioritize rights that solve a specific development bottleneck. A broad excipient license without validated alprostadil performance is less valuable than a narrow platform with demonstrated stability, device compatibility, and scale-up data.

How strong is the CAVERJECT patent estate?

CAVERJECT’s current patent strength is likely lower than its brand and manufacturing strength. The product’s core active ingredient and long-standing injectable formulation are legacy assets. Residual patent risk may persist around later-generation devices, specific formulation claims, or proprietary manufacturing methods, but such claims must be tested against the exact proposed product.

Risk area	Relative risk	Reason
Alprostadil molecule	Low	Established active ingredient
Basic powder formulation	Low to moderate	Familiar excipient architecture
Dual-chamber device	Moderate	Device claims may require design-around analysis
Ready-to-use aqueous product	Moderate to high	Stability and formulation claims may be novel
Manufacturing process	Moderate	Trade secrets and process patents can affect scale-up
Method of use	Low to moderate	Depends on claim scope and remaining patent term
Regulatory exclusivity	Low	Legacy product with no meaningful new-drug exclusivity

What is the commercial opportunity for an improved CAVERJECT product?

The highest-value opportunity is a single-use, preservative-free, ready-to-administer product with a stable delivery device and reduced preparation burden. A second opportunity is a lower-cost generic powder-and-diluent product with dependable availability and simplified instructions.

Product concept	Development complexity	Differentiation	Commercial potential
Conventional generic powder vial	Low to moderate	Low	Price and supply reliability
Improved dual-chamber syringe	Moderate	Moderate	Convenience and reduced preparation errors
Preservative-free presentation	Moderate	Moderate	Tolerability and positioning
Ready-to-use aqueous syringe	High	High	Convenience and potential premium pricing
Lower-pain formulation	High	High if clinically demonstrated	Patient retention and physician preference
Combination intracavernosal product	High	High	Potential efficacy advantage, greater regulatory burden

Revenue exposure is concentrated in the erectile-dysfunction injectable segment rather than the broader PDE5 inhibitor market. The addressable opportunity is smaller than the oral market but can support premium pricing when the product reduces preparation difficulty or improves reliability. A reformulated product may also generate licensing value through regional rights, device partnerships, or contract manufacturing.

Key Takeaways

• CAVERJECT uses alprostadil with lactose, sodium citrate, and alpha-cyclodextrin in its powder formulation.
• The product’s main commercial barriers are formulation stability, sterile manufacturing, device performance, and user convenience.
• Core molecule and legacy-product exclusivity are no longer the principal barriers to generic entry.
• A conventional generic is likely to compete primarily on price, supply continuity, and regulatory execution.
• A ready-to-use or preservative-free product could support stronger differentiation but would require more extensive stability, device, and clinical work.
• The most valuable licensing assets are likely to be delivery systems, sterile manufacturing platforms, and validated stabilization technologies.
• Any final freedom-to-operate conclusion requires claim-level review of current patents against the exact formulation and device design.

FAQs

Can alpha-cyclodextrin be replaced in a CAVERJECT generic?

Potentially, but replacement would require comparative formulation, stability, safety, and regulatory studies. Alpha-cyclodextrin is part of the reference formulation architecture and may contribute to solubility and product performance.

Would a preservative-free CAVERJECT product be patentable?

It could be patentable if the formulation, container, device, stability profile, or manufacturing method satisfies novelty and non-obviousness requirements. Preservative removal alone may not provide sufficient patent scope.

Is a ready-to-use alprostadil syringe an ANDA product?

Not necessarily. A materially different formulation or delivery system may require a 505(b)(2) application rather than a conventional ANDA, depending on FDA’s assessment of pharmaceutical equivalence and the proposed labeling.

What is the most important excipient test for an alprostadil injection?

Long-term and accelerated stability after reconstitution are central, but adsorption, particulate formation, pH, potency, sterility, and delivered-dose testing are also required for a commercial product.

Can a CAVERJECT competitor use the same excipients?

Yes. Excipients are generally not exclusive merely because they appear in the reference product. The proposed product must still meet applicable safety, quality, equivalence, and patent requirements.

References

1. Pfizer Labs. (2023). CAVERJECT and CAVERJECT IMPULSE prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024b). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. International Council for Harmonisation. (2023). ICH Q1A(R2): Stability testing of new drug substances and products. ICH.